Maya Elbert has extensive experience in a wide variety of intellectual property matters, with a focus on patent procurement, counseling, and transactional work in the areas of biotechnology and pharmaceuticals. Her practice includes preparation and prosecution of domestic and international patent applications, patent portfolio management, patentability evaluations, preparation of validity and noninfringement opinions, due diligence evaluations, and freedom-to-operate analyses. Maya's practice also includes patent interferences, inter partes review proceedings, and ex parte reexaminations.
Maya has experience with a wide range of technologies including small molecules, antibodies, gene therapy, biopolymers, nutritional supplements, hematopoietic stem cells, proteins and peptides, nucleic acid technology, and pharmaceutical formulations.
Maya holds a Ph.D. in pharmacology from the Weill Graduate School of Cornell University. Her scientific experience spans the fields of cell biology, molecular biology, biochemistry, and developmental biology. Her doctoral thesis focused on signaling pathways involved in the regulation of cell polarity in yeast and mammalian cells. Maya has published her findings in peer-reviewed scientific journals and has presented at national and international conferences.
Idenix challenges Gilead's patent rights to Sovaldi® (sofosbuvir)
Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent interference against Gilead.
Idenix challenges Gilead's patent rights to methods of treating HCV with Sovaldi® (sofosbuvir)
Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in a patent interference against Gilead.
Acorda Therapeutics wins IPRs
Jones Day served as co-counsel in the successful defense of two of Acorda Therapeutics' Orange Book patents relating to Ampyra®, in IPRs requested by the Coalition for Affordable Drugs (ADROCA) LLC and Kyle Bass et al.
Celgene invests in Acceleron Pharma
Jones Day advised Celgene Corporation in connection with its purchase of Series C-1 Preferred Stock in a private placement by Acceleron Pharma, Inc., a biopharmaceutical company.
- 2011Inequitable Conduct: Analysis of Post-Therasense Court Decisions and the Supplemental Examination Provision of the America Invents Act, Bloomberg Law Reports: Intellectual Property 5(48):13-16
Publications Prior to Jones Day
Par1b promotes cell-cell adhesion and inhibits Dishevelled-mediated transformation of Madin-Darby canine kidney cells, Mol. Biol. Cell 17(8):3345-3355
The yeast Par-1 homologs Kin 1 and Kin 2 show genetic and physical interactions with components of the exocytic machinery, Mol. Biol. Cell 16(2):532-549
The Wnt signaling protein Dishevelled functions with Par-1 in the organization of polarized domains in epithelial cells, Abstract, ELSO Proceedings, p. 252
The role of mammalian Par-1 homologue in MDCK cell polarity, Abstract, Mol. Biol. Cell Suppl. 13:389a
Yeast and mammalian Par-1 homologues are associated with the polarized exocytic machinery, Abstract, ELSO Proceedings, p. 285
Yeast Par-1 homologues are associated with the polarized exocytic machinery, Abstract, Mol. Biol. Cell Suppl 12:71a
- Georgetown University (J.D. 2007); Cornell University, Weill Graduate School of Medical Sciences (Ph.D. in Pharmacology 2004); St. Petersburg State University, Russia (B.S. in Biology 1995)
- New York and registered to practice before the United States Patent and Trademark Office
- Intern, Office of Patent Legal Administration, United States Patent and Trademark Office (Summer 2005)